Serialization and Traceability: Final Agenda: Future Trends: Blockchain in the Pharma Supply Chain - Why the Pharma/Biopharma Industry Needs Blockchain

Serialization and Traceability: Final Agenda: Future Trends: Blockchain in the Pharma Supply Chain - Why the Pharma/Biopharma Industry Needs Blockchain

03/21/2017, 10:30 AM - 12:30 PM

INTERPHEX Innovation Stage

Language:
English

Advanced Digital Ledger Technology™ (ADLT™) has the potential to alter the flow of information within and between trusted partners in the biopharma industry.

ADLT™ is a framework that leverages Blockchain Technology to interconnect systems that do not easily communicate with each other and require that an immutable and auditable record of the origin, changes, and locations of that data for internal and regulatory review. Blockchain Technology is built upon other well vetted technologies such as cryptography and the use of public/private keys that have been in existence since the 1940’s.

The applications range from Supply Chain Management, Regulatory Submissions, Clinical Trial Management, and R&D development and approval.

With the advent of global serialization requirements, the biopharma industry has the ability to gather and access data that was “invisible” to it in the past. ADLT™ can help interconnect the trusted partners in a supply chain network and link API to Patient. By combining ADLT™ with other technologies like the Internet of Medical Things, it is possible to know the exact day, time, and location that a patient took their medication and how the patient responded to their treatment and connect that to the raw materials that an API manufacturer used to produce that tablet. The industry has the ability to gather patient level data and to help promote adherence, while meeting global privacy requirements and preventing counterfeit medicines from entering the supply chain.

There is equal potential for all aspects of the drug development lifecycle such as preventing patients from participating in multiple clinical trials and gathering data from clinical trial sites more efficiently, submitting and constantly keeping regulatory agencies up to date with Marketing Authorizations, gathering data from CROs and other external partners, and ensuring that information within a biopharma company can be easily transferred.

Interconnectivity, auditability, and a clear chain of provenance of data from across a biopharma organization are the key applications for ADLT™ that will reveal previously hidden data and always make an organization inspection ready.

 

 

 

Contributors

  • Darryl Glover

    Speaker

    Chief Clinical Officer

    iSolve, LLC

    Darryl G. Glover, Pharm.D, MBA is a Principal and Chief Clinical Officer (CCO) of iSolve. As CCO, Darryl creates the connections between the...

  • Robert Celeste

    Speaker

    Founder

    Center for Supply Chain Studies

Type of Session

  1. Type of Session
    Keynote Series

We use cookies to operate this website and to improve its usability. Full details of what cookies are, why we use them and how you can manage them can be found by reading our Privacy & Cookies page. Please note that by using this site you are consenting to the use of cookies.